Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions

doi:10.4239/wjd.v17.i4.115058

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (14)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=20

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Publishing Process of This Article

Item

Count

Browse

Download

Sum=0

Apr 15, 2026 (publication date) through Apr 14, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Apr 15, 2026; 17(4): 115058
Published online Apr 15, 2026. doi: 10.4239/wjd.v17.i4.115058

Open in New Tab Full Size Figure Download Figure

Figure 1 Pathophysiological progression and management strategies in diabetic kidney disease. This schematic illustrates the pathogenesis, clinical progression, and current therapeutic approaches in diabetic kidney disease. Created in BioRender (Supplementary material). T1D: Type 1 diabetes; T2D: Type 2 diabetes; GFR: Glomerular filtration rate; RAAS: Renin-angiotensin-aldosterone system; SGLT2: Sodium-glucose co-transporter 2; MRA: Mineralocorticoid receptor antagonist; GLP-1 RA: Glucagon-like peptide-1 receptor agonist; DPP-4: Dipeptidyl peptidase-4; GIP: Glucose-dependent insulinotropic polypeptide.

Citation: Gembillo G, Visconti L, Tranchida V, Nardi C, Calimeri S, Gambuzza ME, Princiotto M, Chinigo C, Soraci L, Santoro D. Evolving strategies for nephroprotection in diabetic kidney disease: From established therapies to novel interventions. World J Diabetes 2026; 17(4): 115058
URL: https://www.wjgnet.com/1948-9358/full/v17/i4/115058.htm
DOI: https://dx.doi.org/10.4239/wjd.v17.i4.115058